Table 2.

Effects of NYT and IL-3 plus EPO on WBC, RBC and platelet counts and hematologic parameters in peripheral blood after 5-FU administration

Day	Treatment	Dose	WBC	RBC	Ht	Hb	PLT
		(mg kg–1 per day)	(×103µl−1)	(×106 µl–1)	(%)	(g dl–1)	(×103 µl–1)
0	Normal	–	3.8 ± 0.1	9.7 ± 0.3	44.2 ± 0.5	14.0 ± 0.1	338 ± 6
	Control	–	3.3 ± 0.2	9.5 ± 0.2	43.8 ± 1.0	14.9 ± 0.3	407 ± 6
	NYT	1	4.1 ± 0.3	9.9 ± 0.1	47.1 ± 0.2	15.5 ± 0.1	467 ± 14
	NYT	10	5.3 ± 0.1*	10.2 ± 0.2	47.1 ± 0.9	15.7 ± 0.2	520 ± 12
	NYT	100	5.2 ± 0.1	10.1 ± 0.1	46.7 ± 0.4	15.3 ± 0.1	432 ± 15
	IL-3/EPO	50 ng + 5 U	4.8 ± 0.3#	10.2 ± 1.3	48.7 ± 1.0#	15.0 ± 0.7	555 ± 12#
10	Control	–	1.9 ± 0.2#	6.0 ± 0.3#	27.3 ± 1.2#	9.5 ± 0.1#	126 ± 9#
	NYT	1	2.4 ± 0.2	6.9 ± 0.2#	30.3 ± 0.3#	10.6 ± 0.3#	109 ± 1
	NYT	10	4.2 ± 0.9#	7.6 ± 0.3#	34.0 ± 1.1#	11.5 ± 0.4#	137 ± 8#
	NYT	100	4.2 ± 0.4#	8.3 ± 0.1#	40.4 ± 0.1#	12.6 ± 0.2#	146 ± 8#
	IL-3/EPO	50 ng + 5 U	2.8 ± 0.4#	8.1 ± 0.2#	41.1 ± 0.2#	13.0 ± 0.1#	163 ± 2#
20	Control	–	14.1 ± 1.7#	7.3 ± 0.2	41.4 ± 0.7	13.2 ± 0.5	1432 ± 165#
	NYT	1	12.9 ± 1.2#	8.8 ± 0.1#	40.0 ± 0.7	12.9 ± 0.1	1226 ± 103#
	NYT	10	16.9 ± 1.5#	8.5 ± 0.2#	40.2 ± 1.0	13.2 ± 0.4	1386 ± 180
	NYT	100	16.2 ± 1.7#	9.0 ± 0.3#	43.5 ± 0.7	13.5 ± 0.2	1493 ± 188
	IL-3/EPO	50 ng + 5 U	13.1 ± 1.6	10.1 ± 1.0#	48.2 ± 0.1#	15.2 ± 0.1#	1512 ± 90#

Mice were injected orally with NYT or subcutaneously with IL-3 (50 ng per mouse) and EPO (5 U per mouse) once daily for 7 consecutive days from 3 days before to 3 days after 5-FU injection. Peripheral blood samples were collected on days 0, 10 and 15, and hematologic parameters were measured by hemocytometer. Data are expressed as the mean±SE of three independent experiments.

^#P < 0.05 compared to normal mice. *P < 0.05 compared to 5-FU-treated mice.